New Zealand markets close in 4 hours 8 minutes

Heron Therapeutics, Inc. (HRTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
8.89+0.36 (+4.22%)
At close: 04:00PM EST
8.78 -0.11 (-1.24%)
After hours: 05:14PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 919.46M
Enterprise value 881.14M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)10.01
Price/book (mrq)7.74
Enterprise value/revenue 10.21
Enterprise value/EBITDA -4.01

Trading information

Stock price history

Beta (5Y monthly) 1.34
52-week change 3-51.42%
S&P500 52-week change 314.56%
52-week high 320.45
52-week low 37.85
50-day moving average 39.39
200-day moving average 312.32

Share statistics

Avg vol (3-month) 32.09M
Avg vol (10-day) 31.97M
Shares outstanding 5101.94M
Implied shares outstanding 6N/A
Float 872.66M
% held by insiders 10.24%
% held by institutions 1109.01%
Shares short (30 Dec 2021) 436.65M
Short ratio (30 Dec 2021) 414.76
Short % of float (30 Dec 2021) 441.13%
Short % of shares outstanding (30 Dec 2021) 435.96%
Shares short (prior month 29 Nov 2021) 431.43M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 312 Jan 2014

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sep 2021


Profit margin -264.58%
Operating margin (ttm)-254.92%

Management effectiveness

Return on assets (ttm)-37.04%
Return on equity (ttm)-115.32%

Income statement

Revenue (ttm)86.3M
Revenue per share (ttm)0.90
Quarterly revenue growth (yoy)16.40%
Gross profit (ttm)-120.88M
EBITDA -217.05M
Net income avi to common (ttm)-228.32M
Diluted EPS (ttm)-2.38
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)202.82M
Total cash per share (mrq)1.99
Total debt (mrq)164.5M
Total debt/equity (mrq)138.42
Current ratio (mrq)4.36
Book value per share (mrq)1.17

Cash flow statement

Operating cash flow (ttm)-210.65M
Levered free cash flow (ttm)-128.37M